Evidence map›Paper›PMID 35055305›Full record

ReviewNanomaterials (Basel, Switzerland)2022

Bacteria-Assisted Transport of Nanomaterials to Improve Drug Delivery in Cancer Therapy.

Carla Jiménez-Jiménez, Víctor M Moreno, María Vallet-Regí

Abstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Bacteria-Based Nanoprobes for Cancer Therapy.International journal of nanomedicine · 2024
    Review
  8. Review
  9. Review
  10. Bacteria associated with glioma: a next wave in cancer treatment.Frontiers in cellular and infection microbiology · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. Recent advances in bacteria-mediated cancer therapy.Frontiers in bioengineering and biotechnology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Carla Jiménez-JiménezCIBER de Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, 28040 Madrid, Spain.
Víctor M MorenoDepartamento de Química en Ciencias Farmacéuticas, Facultad de Farmacia, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria, Hospital 12 de Octubre i+12, 28040 Madrid, Spain.
María Vallet-RegíCIBER de Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, 28040 Madrid, Spain.ORCID 0000-0002-6104-4889

Funding

European Research Council 694160
6 · The paper itself

Abstract

Currently, the design of nanomaterials for the treatment of different pathologies is presenting a major impact on biomedical research. Thanks to this, nanoparticles represent a successful strategy for the delivery of high amounts of drugs for the treatment of cancer. Different nanosystems have been designed to combat this pathology. However, the poor penetration of these nanomaterials into the tumor tissue prevents the drug from entering the inner regions of the tumor. Some bacterial strains have self-propulsion and guiding capacity thanks to their flagella. They also have a preference to accumulate in certain tumor regions due to the presence of different chemo-attractants factors. Bioconjugation reactions allow the binding of nanoparticles in living systems, such as cells or bacteria, in a simple way. Therefore, bacteria are being used as a transport vehicle for nanoparticles, facilitating their penetration and the subsequent release of the drug inside the tumor. This review would summarize the literature on the anchoring methods of diverse nanosystems in bacteria and, interestingly, their advantages and possible applications in cancer therapy.

Indexed as

bacteriacancerdrug deliverynanocarriernanoparticles

Identifiers

PMID35055305
PMCPMC8781131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.